Oncology Today with Dr Neil Love

Research To Practice
Research To Practice

Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

  1. 2h ago

    HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3

    Featuring perspectives from Dr Joshua K Sabari, including the following topics: Jänne PA et al. Final analysis results and patient-reported outcomes from DESTINY-Lung02 — A dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC. J Thorac Oncol 2025;20(12):1814-28. (0:00)Heymach JV et al. Circulating tumor DNA (ctDNA) analysis following zongertinib treatment (tx) in patients (pts) with human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC): Phase Ia/Ib Beamion LUNG-1 study. ESMO 2025;Abstract 2020P. (8:30)Schram AM et al. Beamion PANTUMOR-1: Rationale and design of a phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors. Future Oncol 2026;22(7):795-803. (12:53)Johnson ML et al. Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care in patients with locally advanced/metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain (TKD) mutations. ASCO 2024;Abstract TPS8654. (19:40)Le X et al. SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations. ASCO 2025;Abstract TPS8648. (21:41)Li BT et al. Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). ASCO 2022;Abstract TPS9137. (22:59)Jänne PA et al. Trastuzumab deruxtecan for ERBB2-mutant metastatic NSCLC with or without brain metastases: A secondary analysis of randomized clinical trials. JAMA Netw Open 2025;8(11):e2543107. (24:37) CME information and select publications

  2. 6h ago

    HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2

    Featuring perspectives from Dr Joshua K Sabari, including the following topics: Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00)Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25)Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37) CME information and select publications

  3. 1d ago

    For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress

    Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics: Introduction (00:00)Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)Adjuvant CDK4/6 Inhibitor Therapy (17:14)Practical Considerations with CDK4/6 Inhibitors (29:57)Monitoring and Management of Cytopenias (42:02)CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)Management of Gastrointestinal Adverse Events (1:03:47)CDK4/6 Inhibitors in Unique Populations (1:10:41)Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48) CME information and select publications

  4. 2d ago

    Colorectal Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

    Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Stacey A Cohen and Dr Arvind Dasari, moderated by Dr Bekaii-Saab, including the following topics: Introduction (0:00)Current and Future Role of Immune Checkpoint Inhibition in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Localized and Locally Advanced Colorectal Cancer (CRC) — Dr Cohen (1:45)Clinical Relevance and Practical Utilization of Molecular Residual Disease Analysis in CRC — Dr Dasari (34:08)Recent Advances in Metastatic CRC: Optimizing Immunotherapy and Other Approaches — Dr Bekaii-Saab (1:00:42) CME information and select publications

  5. 3d ago

    Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1

    Featuring perspectives from Dr Mazyar Shadman, including the following topics: The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)Zanubrutinib-based therapy for treatment-naïve CLL (12:32) CME information and select publications

  6. 3d ago

    Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2

    Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22)Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02) CME information and select publications

  7. 5d ago

    Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway

    Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00)Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35)Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23)Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06)Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications

  8. Jul 23

    For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress

    Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics: Introduction (00:00)Overview of Ovarian Cancer (OC) (2:12)Role of PARP Inhibitors in Advanced OC (4:56)Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)Role of Relacorilant in Advanced OC (57:08)Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12) NCPD information and select publications

See All (467)

Ratings & Reviews

4.8
out of 5
61 Ratings

About

Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.

Information

More From Research To Practice